











CHARLINE MUKASA SANGANY 
 
 
Submitted in partial fulfilment of the requirement for the degree of 
 
 




Discipline of Optics and Imaging 
Doris Duke Medical Research Institute 
College of Health Sciences 






This study contains original work done by the author, it has not been submitted in any form to 
any other University. Work done by other authors have been used and duly acknowledged in the 
text. 
The research within this dissertation was conducted in the Optics and Imaging Centre, Doris Duke 
Medical Research Institute, College of Health Science, University of Kwa-Zulu Natal, Durban, 






Charline Sangany      Professor T. Naicker 













I, Charline Sangany (211559876) declare that: 
i. The research reported in this dissertation, except where otherwise indicated is my original 
work. 
ii. This dissertation has not been submitted for any degree or examination at any other 
university. 
iii. This dissertation does not contain other person’s data, pictures, graphs or other 
information, unless specifically acknowledged as being sourced from other persons. 
iv. This dissertation does not contain other persons writing, unless specifically 
acknowledged as being sourced from other researchers. Where other sources have been 
quoted, then: 
a. Their words have been re-written, but the general information attributed by them 
has been referenced. 
b. Where their exact words have been used their writing had been placed inside 
quotation marks and referenced. 
c. Where I have reproduced a publication of which I am an author, co-author, I have 
indicated in detail which part of the publication was written by myself and have 
fully referenced such publications. 
v. This dissertation does not contain text, graphics, or tables copied and pasted from the 
internet, unless specifically acknowledged and the source being detailed in the 
dissertation and the reference sections. 
 
 









All letters cannot find the words to say... 
All the words cannot express my gratitude, love, respect... 
I dedicate this thesis... 
To my Lord Jesus Christ all powerful, who inspired me and guided me in the right path; I owe 
you what I became. Praise and thanks to your clemency and mercy. 
To my dad Francois Sangany, thank you for your endless love and support that you have shown 
me through my life. Without you I would not have been granted this wonderful opportunity 
therefore I dedicate this Dissertation to you as my inspiration. 
To my mother Hortense Tshikomba, dear mama, thank you for countless and huge sacrifices 
that you have made for my education and well-being. Your love, your goodness, your extreme 
generosity and your support are limitless. Your dedication was for me a constant 
encouragement. Today, I put in your hands the result of your dedication and your sacrifice as 
well as the expression of my love and my respect for you. Your prayers have been for me, very 
supportive. May God give you long life and happiness and may your blessing be with me 
always. I love you. 
To all the Sangany and Bokana, you are my joy, my strength, my positive energy... 
To all my friends for unforgettable friendship, countless memories, to the infinite loyalty, to the 
strong links which have sprayed our cohesion. This work is a testimony and recognition of your 
noble morals. 
To all who are dear to me and I forgot to mention. To anyone who spent a moment to help, 
advice, encourage or simply smiled at me 
Charline 







This research was funded by: 
 The College of  Health Science, University of KwaZulu-Natal; 
























I express my gratitude to:  
 My supervisor Professor Thajasvarie Naicker for allowing me to be part of the Placental 
Research Group and for giving me confidence. Thank you for everything I learned during 
my journey as a master’s postgraduate student and for the kindness that you have put in 
our human relationship. Thank you also for your scientific rigour and your constant 
availability. 
 Professor Jagidesa Moodley for agreeing to judge this work professionally; it is an honour 
for me; 
 The Optics and Imaging Centre, Doris Duke Medical Research Institute, College of 
Health Sciences, for providing research facilities to conduct the study; 
 Dr Wilbert Sibanda for statistical analysis; 
 Dr Felix Onyangunga for contributing with his knowledge in obstetrics and gynaecology 
toward this thesis; 
 My father Francois Sangany for allowing me to travel and for supporting me financially. 
Your help, your confidence, the dimension of your authorship and your philosophy of life 
has been one of the pillars of this thesis. I thank you with all my love; 
 All those who, through their collaboration, their help and their sympathy, helped in the 













TABLE OF CONTENTS 
PREFACE ..................................................................................................................................... i 
DECLARATION ......................................................................................................................... ii 
DEDICATION ............................................................................................................................ iii 
FUNDING ................................................................................................................................... iv 
ACKNOWLEDGEMENTS ........................................................................................................ v 
LIST OF ABBREVIATIONS .................................................................................................. viii 
LIST OF FIGURES .................................................................................................................... x 
LIST OF TABLES ..................................................................................................................... xi 
ABSTRACT ............................................................................................................................... xii 
CHAPTER I ................................................................................................................................. 1 
BACKGROUND AND LITERATURE REVIEW ................................................................... 2 
1.1 Preeclampsia ........................................................................................................................ 2 
1.1.1 Epidemiology and risk factors ...................................................................................... 2 
1.1.2 Pathogenesis of Preeclampsia ....................................................................................... 3 
1.2 Human immunodeficiency virus infection .......................................................................... 5 
1.2.1 Epidemiology ................................................................................................................ 6 
1.2.2 Influence of Human Immunodeficiency Virus infection on pregnancy ........................ 6 
1.3 HIV associated Preeclampsia .............................................................................................. 6 
1.4 Fibroblast Growth Factors (FGFs)....................................................................................... 7 
1.4.1 FGF superfamily and subfamily ................................................................................... 7 
1.4.2 Fibroblast growth factor receptor and signaling pathway ............................................. 8 
1.4.3 FGF Mechanism of action............................................................................................. 9 
1.4.4 Basic Fibroblast Growth Factor (FGF-2) .................................................................... 10 
1.5 Hypothesis ......................................................................................................................... 12 
1.6 Aim and objectives ............................................................................................................ 12 
CHAPTER II ............................................................................................................................. 13 
Abstract .................................................................................................................................... 16 
Introduction ............................................................................................................................. 17 
Material and Methods .............................................................................................................. 18 
Study population .................................................................................................................. 18 
Samples ................................................................................................................................ 19 
Bio-Plex Multiplex immunoassay ........................................................................................ 19 
Statistical analysis ................................................................................................................ 19 
vii 
 
Results ..................................................................................................................................... 19 
Clinical characteristics and demographic data ..................................................................... 19 
FGF-2 serum concentration ................................................................................................. 22 
Discussion ................................................................................................................................ 23 
Conclusion ............................................................................................................................... 25 
Declaration of interest ............................................................................................................. 25 
Acknowledgements ................................................................................................................. 26 
References ............................................................................................................................... 26 
CHAPTER III ............................................................................................................................ 31 
SYNTHESIS .............................................................................................................................. 32 
Conclusion ............................................................................................................................... 35 
CHAPTER IV ............................................................................................................................ 36 
REFERENCES .......................................................................................................................... 37 
CHAPTER V ............................................................................................................................. 51 
Appendices ................................................................................................................................. 52 
Appendix 1 .............................................................................................................................. 52 















LIST OF ABBREVIATIONS 
 
AIDS Acquired immunodeficiency syndrome  
ART Antiretroviral therapy 
AKT Protein kinase B 
ECM Extracellular matrix 
EOP Early onset preeclampsia 
ER Endoplasmic reticulum 
ERS Endoplasmic recticulum stress 
EVT Extravillous trophoblast 
FGF Fibroblast growth factor 
FGF-1 Acidic fibroblast growth factor 
FGF-2 Basic fibroblast growth factor 
FGFR Fibroblast growth factor receptor 
HAART Highly active antiretroviral therapy 
HELLP Hemolysis  elevated liver enzymes and low platelet count 
HIF Hypoxia-inducible factor 
HSPG Heparan sulphate proteoglycan 
HIV Human immunodeficiency virus 
IFN Interferon 
Ig Immunoglobulin 
IL-6 Interleukin 6 




LOPE Late onset preeclampsia 
MAPK Mitogen-activated protein kinases 
N Normotensive 
N+ Normotensive HIV positive 
N- Normotensive HIV negative 
NF-kb Nuclear factor kb 
NO Nitric oxide 
NK Natural killer cell 
PlGF Placental growth factor 
PE Preeclampsia 
PI Protease inhibitor 
RAS Receptor activated serine kinases 
VEGF Vascular growth factor 
SA South Africa 
SFlt soluble fms-like tyrosine kinase (sFlt-1) 
TGF Transforming growth factor 
Th T helper  
UNAIDS United nations programme on HIV and AIDS 
UNICEF United nations international children’s emergency fund 










 CHAPTER I  
Figure 1.1 Physiological modification of the spiral arteries in normal pregnancy 
and in preeclampsia. 
4 
Figure 1.2 Phylogenetic tree of human FGF family 8 
Figure 1.3 Diagram of the mechanism of action of FGF  9 
Figure 1.4 Illustration of the molecular mechanism of unconventional secretion 





Figure 1  FGF-2 expression based on HIV status 21 
Figure 2 FGF-2 expression based on pregnancy 21 

















 CHAPTER II  
Table 1 Clinical profile and demographic data across all study groups. 20 
Table 2  
 























Background: HIV/AIDS and preeclampsia (PE) remain the main causes of maternal death in 
sub-Saharan Africa. In South Africa, 12% and 38% of maternal deaths are attributed to PE and 
HIV/AIDS respectively. Both HIV infection and PE are characterised by opposing inflammatory 
responses that affect cell signalling. Basic fibroblast growth factor FGF-2 is a multifunctional 
protein that regulate structural reorganization of uterine and placental vascular bed during 
pregnancy. In light of the high prevalence of HIV infection and PE in the province of KwaZulu-
Natal, this study investigates FGF-2 expression in HIV associated PE using the Bio-Plex 
Multiplex Immunoassay. 
Method: Retrospectively collected serum samples from 40 normotensive pregnant and 40 
preeclamptic women attending the antenatal clinic in a large regional hospital in eThekwini, South 
Africa were analysed. Samples were further stratified according to HIV status. FGF-2 was 
quantified using a Bio-Plex immunoassay. 
Results: A downregulation of FGF-2 expression was observed in PE irrespective of HIV status 
(p=0.0011). Similarly, a downregulation of FGF-2 expression was reported in HIV positive 
patients irrespective of pregnancy type (p=0.0471). Across all study groups, there was a 
significant difference in the expression of FGF-2 between normotensive HIV negative vs pre-
eclamptic HIV negative (p=0.0255). A significant difference was also noted between 
normotensive HIV negative vs pre-eclamptic HIV positive (p = 0.0002) and between 
normotensive HIV positive vs pre-eclamptic HIV positive (p = 0.0149). 
Conclusion: This study demonstrates a downregulation of FGF-2 in PE implicating a defect in 
the endothelial loop feedback. The downregulation of FGF-2 in HIV infected subjects may be 
attributed to HIV Tat that interferes with the Src homology, which phosphorylates FGF-2. The 
use of highly active antiretroviral (HAART) results in endothelial toxicity and vascular 
dysfunction which affect FGF expression. Future studies will include a genetic appraisal of the 

































BACKGROUND AND LITERATURE REVIEW 
 
1.1 Preeclampsia  
Preeclampsia (PE) is an obstetric condition that clinically occurs after the 20th gestational week. 
It is characterised by hypertension with a diastolic blood pressure ≥ 90 mmHg and a systolic blood 
pressure ≥140 mmHg, recorded twice in less than four hours apart, with proteinuria > 300 mg/24h, 
in a previously normotensive woman (Brown et al., 2018). The severity of PE lies in the possible 
occurrence of severe maternal complications (hemolysis elevated liver enzymes and low platelet 
count (HELLP) syndrome, eclampsia, haemostasis disorder, retro-placental hematoma and death) 
and perinatal complications (hypotrophy, induced prematurity and death in utero) (Ai-ris et al., 
2018). PE may be classified as early onset (EOPE) or late onset (LOPE) according to the 
gestational age at diagnosis (Tranquilli et al., 2013). EOPE is diagnosed before 34 weeks of 
gestation and LOPE after 34 weeks of gestation (Brown et al., 2018; Tranquilli et al., 2013).  
The aetiology of PE remains unknown. Studies suggest that PE could be established by inadequate 
signalling between the placenta and the mother (Brown et al., 2018). Nonetheless, abnormal 
placentation related to immune maladaptation and angiogenic dysregulation are implicated in PE 
development (Naicker et al., 2003). Preeclampsia is biologically associated with an increase of 
anti-angiogenic factors namely soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin 
(sEng) that impair the signal of  pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF) and placental growth factor (PlGF) in the maternal circulation (Karumanchi et al., 2015). 
The pathological origin of PE is suggested to be the placenta hence the only curative treatment is 
the removal of the foetus allowing the delivery of the placenta (Ijomone et al., 2018). 
1.1.1 Epidemiology and risk factors  
Approximately 50 000 women worldwide die annually from PE (WHO, 2018). Preeclampsia 
affects 5-8% of pregnancies worldwide (Adams et al., 2016). In high-income countries, PE has a 
prevalence of 2-5% (Iyengar, 2001; Villar et al., 2006). However, in low-middle income 
countries, it occurs more frequently and is the primary cause of direct maternal mortality (15-
20%) and morbidity, peri-natal death and intra-uterine growth retardation (Sharma et al., 2018; 
Alkema et al., 2016).  
In South Africa, 14.8% of maternal deaths are attributed to hypertension in pregnancy with 
PE/eclampsia accounting for the majority of deaths (Moodley, 2018). Nulliparity (Myers, 2017), 
multiparity (Paré et al., 2014), age (below 18 and above 40 years) (English et al., 2015), medical 
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history of pre-existing high blood pressure (English et al., 2015), trophoblastic disease (Wright et 
al., 2015), obesity (Duckitt and Harrington, 2005), and prior history of PE are associated with a 
high probability of PE development (Duley et al., 2007). Other risk factors include duration of 
exposure to paternal sperm (Lie et al., 1998) and environmental factors such as climate and 
poverty (Fisher et al., 2015).  
1.1.2 Pathogenesis of Preeclampsia 
Several theories explaining the pathogenesis of PE have been put forward that directly or 
indirectly contribute to placental malfunction.  
1.1.2.1 Angiogenesis 
Angiogenesis is the formation of new capillary/blood vessels and occurs in a wide range of 
important biological processes (Heymach et al., 2016). In human pregnancy, the formation of the 
placenta undergoes angiogenesis, vasculogenesis, and pseudovasculogenesis as cytotrophoblasts 
convert from an epithelial to an endothelial phenotype (Karumanchi et al., 2015). Cytotrophoblast 
invasion generates vascular changes that favour materno-placental blood exchange necessary for 
fetal development (Karumanchi et al., 2015). Placental angiogenesis is characterized by an 
invasion of spiral arteries in the decidua by extravillous cytotrophoblasts (EVT) (Thakoordeen et 
al., 2017). Vascular changes are mediated by an increase in local and systemic VEGF secretion 
favouring vascular proliferation (Govender et al., 2013). 
Failure of angiogenesis during early development has been linked to the pathogenesis of PE 
(Figure 1.1). The placenta in preeclamptic women produces an excess of anti-angiogenic factors 
(sFlt-1 and Eng) that enter the maternal circulation and impair vascular endothelial cell signaling 
of pro-angiogenic factors such as VEGF and PlGF (Karumanchi et al., 2015). The study of factors 
that are responsible for insufficient trophoblastic invasion is limited as PE is diagnosed after the 
natural process of trophoblastic invasion. Therefore, abnormalities observed in PE do not 








Figure 1.1: Physiological modification of the spiral arteries and trophoblast invasion in 
normal pregnancy and in PE. Preeclampsia is characterized by ineffective trophoblast invasion and 
defective vascular remodelling leading to reduced maternal blood flow, which in turn may compromise 
foetal growth. Adapted from (Karumanchi et al., 2015). 
 
 
1.1.2.2 The oxidative stress theory 
One of the intrinsic trophoblastic factors involved in uteroplacental artery invasion is the 
surrounding oxygen tension. Extravillous trophoblasts (EVTs) encounter an increasing oxygen 
gradient during their migration to the spiral arteries and the more the tension increases, the more 
they differentiate into an invasive phenotype (Genbacev et al., 1997). Abnormal remodelling of 
the spiral arteries results in an abnormal oxygen supply to the placenta leading to a hypoxic state 
causing activation of diverse mechanisms that result in a high level of oxidative stress and 
inflammation (Salsoso et al., 2017). This phenomenon results from increased expression and 
activity of hypoxia inducible factor 1a (HIF-1α) that ends in nuclear factor kB (NF-kB)-dependent 
inflammation (Salsoso et al., 2017). HIF-1 induces transcription of TGF-β3 which inhibits 
trophoblast invasion (Caniggia et al., 1999). Oxidative stress results in endothelial dysfunction 
and increases endoplasmic reticulum stress (ERS), a condition evidenced by increased unfolded 
protein response (UPR) and trophoblast apoptosis (Caniggia et al., 1999). 
 
 
Normal pregnancy Preeclampsia  
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1.1.2.3 Adhesion molecules 
A study conducted by Zhou et al in 1993 revealed an abnormal pattern of molecules on the surface 
of cytotrophoblasts in placental bed biopsies performed in PE. In PE, EVTs lose their ability to 
switch from a proliferative phenotype to an invasive phenotype (Zhou et al., 1993). Thus, the 
expression of integrins α6β4, αvβ6 and E-cadherin persists whereas integrin α1β1 does not appear 
on the EVT surfaces (Karumanchi et al., 2015).  
1.1.2.4 Immune maladaptation  
T-helper (Th) 1 and Th2 cytokines play a role in cell-mediated and humoral immunity. The Th1 
immune response inhibits the Th2 response and vice versa by cytokine production (Mikovits et 
al., 1994). In healthy non-pregnant women, there is a balance between the Th1 and Th2 response 
(Laresgoiti-Servitje et al., 2010). In a normal pregnancy, with the presence of the placenta, a shift 
from the Th1 to Th2 immune response occurs (Laresgoiti-Servitje et al., 2010).  
However, in PE, the regulation of the maternal immune system is further altered as this shift does 
not occur (Saito et al., 2010). Wegmann et al. (1993) proposed that the placenta is a Th2 organ 
that stimulates the production of Th2 cytokines in the maternal immune system. When the 
placenta is abnormal, the maternal immune system responds by producing Th1 cytokines 
(Wegmann et al., 1993). Additionally, transforming growth factor-β cytokines surge thereby 
retarding cytotrohophoblast migration (Wegmann et al., 1993, Laresgoiti-Servitje et al., 2010). 
Moreover, in PE, syncytiotrophoblast fragments are increased in maternal circulation due to the 
ischemic placenta which is possibly responsible for triggering the Th1 response (Germain et al., 
2007). Th2 cytokines respond to extracellular infection and are known to suppress the immune 
system (Sargent et al., 2006). In HIV infected patients there is a decrease in the Th1 and an 
increase in Th2 cytokines (Clerici and Shearer, 1993). However, the circulating levels of 
cytokines in PE is still conflicting (Kumar et al., 2013). 
 
1.2 Human immunodeficiency virus infection 
Human immunodeficiency virus (HIV) is an RNA virus from the retroviridae family, 
characterized by the presence of an enzyme-reverse transcriptase (Garofalo et al., 2016). HIV 
infection is known to alter the body’s immune response by infecting immune cells and making 
the body more vulnerable to infections (McCormack et al., 2016). Its preferred targets are the 
CD4 + T lymphocyte through their CCR5 and CXCR4 receptors (Bengoa et al., 2017). HIV Tat 
plays an important role in the activation of the transcriptional proviral DNA and it is known as a 
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powerful angiogenic factor (La Venuta et al., 2015). Opportunistic diseases that take advantage 
of the reduced immunity lead to the Acquired immunodeficiency syndrome (AIDS) which is fatal 
(Bengoa et al., 2017). 
1.2.1 Epidemiology 
Sub-Saharan Africa accounts for 56% of people living with HIV infection globally (UNAIDS, 
2018). In 2017, women accounted for a disproportionate 59% of new adult HIV infections (> 15 
yrs) (UNAIDS, 2018). South Africa (SA) is home to the largest global HIV epidemic (UNICEF 
Eastern and Southern Africa, 2018). In SA, 13.1% of the total population is HIV positive, one-
fifth been women in their reproductive ages (15–49 years) (Statistics South Africa, 2018). The 
province of KwaZulu-Natal (KZN) is the global “HIV hotspot” where 40.8% of adults (aged 15 
years and older) are living with HIV infection (Cuadros et al., 2018). The highest prevalence of 
HIV infected parturients (37%) occurs in the province of KZN (Statistics South Africa, 2018). 
Hence, health care professionals providing maternity care are faced with a severe dilemma.  
1.2.2 Influence of HIV infection on pregnancy 
Premature births and foetal hypotrophy are more frequent in the cohorts of women infected with 
HIV compared to uninfected women (Adam, 2015). In the absence of antiretroviral therapy 
(ART), the severity of the immunosuppression is also a risk factor for obstetric complications or 
foetal malformations (Yudin et al., 2016). The benefit of ART in pregnancy, including the 
reinforcement of immune defences, is counterbalanced by its potential toxic effect (Danforth et 
al., 2017). A European study found that treatment with protease inhibitors (PI) was associated 
with a significant increase in the rate of premature delivery (Woodsong and Holt, 2015). Other 
preliminary studies have suggested that the use of triple ART is associated with an increased rate 
of PE (Maharaj et al., 2017). 
 
1.3 HIV associated Preeclampsia 
HIV and PE are disorders that affect the immune response by causing an alteration in both the 
innate and the adaptive immunity (Moodley, 2013). As these disorders generate an inflammatory 
response, activated neutrophils, macrophages and NK cells that travel to the inflammatory site 
induce endothelial dysfunction, while activated T cells may support inadequate tolerance during 
pregnancy (Moodley, 2013). Previous data have indicated that the expression of inflammatory 
cytokines such as TNF-alpha, IL-1beta, and IFN-gamma in PE are similar to those in HIV infected 
patients (Udenze et al., 2015). The combination of these cytokines as found in conditioned media 
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from activated T cells induce normal endothelial cells to acquire the features of being responsive 
to the effects of HIV Tat protein (Maharaj et al., 2017). Both large and small vessel endothelium 
chronically exposed to inflammatory cytokines produce and release angiogenic factors in the 
absence of cell death, a key feature of PE (Maharaj et al., 2017). Highly active antiretroviral 
therapy (HAART) is reported to enhance maternal immune reconstitution by re-establishing the 
mother’s immune response to foetal antigens, however it makes  HIV infected women susceptible 
to the development of PE (Adams et al., 2016).  
 
1.4 Fibroblast Growth Factors (FGFs) 
Cellular signalling is a complex communication system that governs the fundamental functional 
processes of cells and coordinates their activity (Wright and Dyson, 2015). The ability of cells to 
perceive and correctly respond to their microenvironment is at the root of their developmental 
processes such as in proliferation, differentiation, migration, invasion, and apoptosis (Sun et al., 
2015). A correct signalling pathway contributes to a well-established immune response as well as 
to normal tissue homeostasis (Sun et al., 2015). Both HIV infection and PE are characterised by 
an inflammatory response (Maharaj et al., 2017) therefore, assessing analytes that participate in 
cell signalling pathways in both physiological and pathological conditions is important. 
The fibroblast growth factors (FGF) are multifunctional proteins that, among other roles, regulate 
structural reorganization of uterine and placental vascular bed during pregnancy (Chrusciel et al., 
2010). Fibroblast growth factors are synthesized by endothelial cells and fibroblasts (Blotnick et 
al., 1994). Fibroblast growth factors are only released on physiological and pathological demand 
hence their role in tissue repair and in angiogenesis is vital (Ornitz and Itoh, 2015). 
1.4.1 FGF superfamily and subfamily 
According to a phylogenetic analysis, the human FGF superfamily consists of 22 members or 
ligands (Figure1.2).  These may be further stratified into seven subfamilies: FGF 1/2, FGF 4/5/6, 
FGF 3/7/10/22, FGF 8/17/18, FGF 9/16/20, FGF 11/12/13/14, and FGF 19/21/23, coded by as 
many different genes varying between 155 and 268 amino acids (Nunes et al., 2016).  
Members of FGF-1 to 10 bind to the fibroblast growth factor receptors (FGFR) (Nunes et al., 
2016). Fibroblast growth factor ie. FGF-11to 14, also known as FGF-homologue 1-4 (FHF-1-
FHF4) are involved in intracellular processes, but they do not bind to FGFRs (Nunes et al., 2016). 
The FGF-18 subfamily is involved in cell development and morphogenesis in various tissues, 
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including cartilage. The FGF-19 was only described in humans whilst FGF-15 only in mouse. 












Figure 1. 2: Phylogenetic tree of human FGF family. Adapted from (Ornitz and Itoh, 2015). 
 
1.4.2 Fibroblast growth factor receptor and signaling pathway 
In humans, the FGFR consists of four members: FGFR1, FGFR2, FGFR3 and FGFR4 
(Sarabipour and Hristova, 2016). Each FGFR comprises three extracellular immunoglobulin-
like domains i.e., IgI, IgII, and IgIII that are important in receptor dimerization; a transmembrane 
domain and a tyrosine kinase intracellular domain (Sarabipour and Hristova, 2016). The FGFR1-
3 have a varied IgIII domain and use it alternatively to generate different isoforms that are 
expressed in different types of tissues with diverse binding specificities (Ornitz and Itoh, 2015). 
FGFR4 can only use its unique IgIII form.  
FGF binds to heparan sulfate proteoglycan (HSPG) that are present in the extracellular matrix 
(ECM); mediated by the IgIII domain (Sarabipour and Hristova, 2016). This binding triggers a 
signal causing tyrosine kinase phosphorylation and FGFRs activation (Sarabipour and Hristova, 
































to the phosphorylated tyrosine at the cytosolic part of the receptor (Yashiro and Matsuoka, 2016). 
Finally, this triggers a number of signalling pathways that mediate specific cellular responses 
(Ornitz and Itoh, 2015). The best understood pathways are the RAS/MAP kinase pathway, PI3 
kinase/AKT pathway, and PLCγ pathway (Yashiro and Matsuoka, 2016). These signalling 
pathways contribute to cell proliferation, migration, differentiation, and angiogenesis (Yashiro 
and Matsuoka, 2016). 
1.4.3 FGF Mechanism of action  
The FGF family may also be divided into three groups according to their mode of action 
(Figure1.3). These include:  
a) Paracrine action- mediated by five sub-families namely FGF-1/2, FGF -4/5/6, FGF -
3/7/10/22, FGF -8/17/18 and FGF -9/16/20; 
b) Endocrine action- mediated by FGF-19/21/23 subfamily; 









Figure 1.3: Diagram of the mechanism of action of FGF through paracrine, intracrine and 
endocrine manner. Adapted from (Nunes et al., 2016). 
 
Paracrine FGF contains a cleavable N-terminal secreted signal peptide (Revest et al., 2000). The 
bipartite secreted signal peptide sequence of FGF-9/16/20 is not cleaved in mature proteins 
(Revest et al., 2000). However, the FGF1/2 subfamily lacks the N-terminal signal peptide 
sequence and is released from damaged cells by an exocytotic mechanism of which the ER/Golgi 
pathway is not required (Zacherl et al., 2015;Mohan et al., 2010; Nickel, 2010). Paracrine FGFs 
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are heparan binding molecules that bind to the tyrosine kinase FGFR (Nickel, 2010). This results 
in functional dimerization, receptor transphosphorylation, and the activation of downstream 
signalling pathways (Ornitz and Itoh, 2015). Paracrine FGFs mediate the biological response of 
neighbouring cells from a distance, and their affinities for heparan-like molecules of the ECM 
regulate the range of their signalling (Antoine et al., 1997). 
Like paracrine FGFs, endocrine FGF function by binding to FGFRs. However, their affinity for 
heparin sulfate is not that strong thus they are restricted to act in an endocrine manner (Zhang et 
al., 2006; Goetz et al., 2007). Intracrine FGFs are intracellular proteins that primarily work as 
regulators of the electrical excitability for neurons (Goldfarb et al., 2007; Xiao et al., 2007).  
1.4.4 Basic Fibroblast Growth Factor (FGF-2) 
The first members of the FGF family “FGF 1/2” was described in 1986 (Jaye et al., 1986; 
Abraham et al., 1986). Fibroblast Growth Factor-1 was isolated at an acidic pH, and was named 
"acidic fibroblast growth factor" whereas FGF-2 was isolated at basic pH, hence termed "basic 
fibroblast growth factor”. Basic fibroblast growth factor is a potent mitogen and powerful 
angiogenic factor that is involved in repair of damaged tissues (Sonmez and Castelnuovo, 2014). 
Basic fibroblast growth factor is a heparan-binding protein involved in a variety of pathological 
conditions including angiogenic dysregulation and solid tumour growth hence it is regarded as a 
target for cancer chemopreventative and therapeutic strategies.  
Basic fibroblast growth factor lacks a signal peptide-mediated sequence and is released by direct 
translocation across the plasma membrane (Rothman and Wieland, 1996) or through vesicular 
intermediates such as autophagosomes or exosomes derived from multivesicular bodies 
(Rabouille et al., 2012). An unconventional mechanism involves FGF-2 oligomerization that 
forms pores in the plasma membrane thus allowing direct protein translocation (La Venuta et al., 
2015). As illustrated in Figure 1.3, the translocation process is mediated by FGF-2 recruitment by 
the phosphatidylinositol 4,5-bisphosphate PI(4, 5)P2 (Zacherl et al., 2015). As a result, FGF-2 
undergoes oligomerization that, in turn, causes membrane insertion and the formation of 
membrane pores (Steringer et al., 2012)  
The main features of the unconventional secretion of FGF-2 are:  
1. Serial molecular connections with the inner leaflet along with Tec kinase dependent 
tyrosine phosphorylation of FGF-2, 
2.  PI(4, 5)P2 dependant oligomerization and membrane pore formation, 




Figure 1.4: Illustration of the molecular mechanism of unconventional secretion of FGF-2. 
FGF2 secretion is mediated by direct translocation across the plasma membrane. This process involves 
sequential interactions of FGF-2 with components at the inner leaflet, including ATP1A1 (the α subunit of 
the Na/K ATPase), the phosphoinositide PI(4,5)P2, and Tec kinase. The ATP1A1 is efficient as its 
downregulation was shown to cause a substantial drop in FGF-2 secretion. The phosphoinositide PI(4,5)P2 
dependant membrane binding contributes to the secretion of FGF-2, a protein that lacks peptide signal. The 
HIV accessory protein called Tat exits the cell in the same manner as FGF. Tec kinase is a non-tyrosine 
kinase receptor that regulates FGF-2 secretion. It is also known in the context of immune cell development 
and activation. Tec kinase phosphorylates FGF-2, a process that favours the formation of membrane pores 
by FGF-2 oligomers. Tec kinase contains a pleckstrin homology domain that mediates PI(3,4,5)P3 –
dependant membrane recruitment. Tec kinase becomes phosphorylated by plasma membrane-resident Src 
kinases or by autophosphorylation within its activation loop resulting in enzymatic activation. Heparan 
sulfate proteoglycans are required to trap FGF-2 on cell surfaces, the final step in the overall process of 
FGF-2 secretion. Adapted from (Zacherl et al., 2015). 
 
1.4.4.1 Basic Fibroblast growth factor & HIV infection 
The molecular mechanism by which FGF2 is secreted from cells seems to be used by other 
proteins such as the HIV-1 transactivator of transcription (HIV-Tat) (Ruben et al., 1989). HIV-
Tat is a regulatory protein that is synthesised early in HIV infection, involved in viral gene 
expression by enhancing transcriptional rates and responsible for viral variability (Ruben et al., 
1989). 
Like FGF-2, HIV Tat is a protein that lacks a signal peptide. Despite the lack of signal peptide, 
HIV Tat can be secreted from damaged or infected cells, therefore, it may be classified as an 





be released from infected T cells in a PI(4,5)P2-dependent manner which is similar to the exit 
manner of FGF-2 (Rayne et al., 2010) . In addition, HIV-Tat has been demonstrated to bind to 
heparan sulfate proteoglycans (Debaisieux et al., 2012), which contributes to HIV-Tat secretion 
similarly to those of FGF-2 (Nickel, 2007). Therefore, the activities of FGF-2 and HIV Tat are 
synergistic (Zhou et al., 2013). 
1.4.4.2 Basic Fibroblast Growth Factor (FGF-2) & Preeclampsia  
In PE, there is a deregulation of decidual and placental FGFR2 expression (Marwa et al., 2016). 
Nonetheless, FGF-2 is widely expressed during embryonic development and acts by controlling 
neovascularization (La Venuta et al., 2015). Variation in FGF-2 gene is associated with 
hypertension, which was attributed to upregulation of FGF-2 expression in glomerular mesangial 
and endothelial cells (Marwa et al., 2016). To our knowledge, there is no available data on the 
pathological condition of PE comorbid with HIV infection.  
 
1.5 Hypothesis  
Basic Fibroblast growth factor would be altered in the opposing immune responses of PE and 
HIV infection. 
 
1.6 Aim and objectives 
This study investigated FGF-2 expression in HIV associated preeclampsia using the Bio-Plex 
Multiplex Immunoassay.  
Objectives will include: 
 To determine the effect of pregnancy type (normotensive and preeclampsia) on the 
expression of FGF-2 irrespective of HIV status,  
 To determine the effect of HIV status (HIV positive and HIV negative) on FGF 
expression irrespective of pregnancy type, 
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Purpose:  Cell signalling is vital to ensure successful trophoblast invasion, hence this study 
assessed the level of serum basic fibroblast growth factor (FGF-2) in HIV associated 
preeclampsia. 
Method: Using a Bio-plex Multiplex Immunoassay, FGF-2 serum concentration (pg/ml) was 
analysed in blood sera collected from 80 pregnant women attending a large regional hospital in 
Durban, South Africa. Study groups consisted of normotensive and preeclamptic pregnant women 
stratified according to their HIV status. All HIV positive groups received highly active 
antiretroviral therapy (HAART). 
Results: In this study, we report a significant decrease of FGF-2 serum levels (p=0.0011) in 
preeclamptic compared to normotensive pregnant women, irrespective of HIV status. Also, there 
was a significant decrease in FGF-2 serum levels (p=0.0471) in HIV positive compared to HIV 
negative group, irrespective of pregnancy type. Across all groups, a significant difference 
(p=0.0020) in FGF-2 expression was noted.  
Conclusion: This study demonstrates a down-regulation of FGF-2 expression in preeclamptic 
compared to normotensive pregnant women and may be attributed to the defective trophoblast 
invasion and/or to preeclampsia severity.  The decline in FGF-2 expression in HIV infection is 
probably due to the effect of HIV Tat protein on angiogenesis.  Further investigations on the effect 
of HAART on FGF-2 expression are required. 
 











South Africa (SA) is the 4th largest Human Immunodeficiency Virus (HIV) epidemic in the world 
[1]. In SA, the HIV prevalence rate is 13.1% with 19.0% of infections occurring within the 
reproductive age (15–49 years) [2, 3]. In the province of KwaZulu-Natal (KZN) SA, the overall 
HIV prevalence in women is 39.0% hence is a serious obstetric problem [4]. In SA, 14.8 % of 
maternal deaths emanate from hypertension in pregnancy with preeclampsia (PE) accounting for 
83% of deaths [5]. The prevalence of PE in SA is 12% [6]. 
Preeclampsia is a pregnancy specific complication unique to humans that affects 3 to 10% of 
pregnancies worldwide [7]. It is characterised by de novo hypertension (blood pressure ≥ 140/90 
mm Hg) and proteinuria (> 300g/24 h or ≥ + 1 dipstick) occurring after 20 weeks of pregnancy 
[8]. The underlying pathogenesis of PE is defective trophoblast invasion that eventuates in an 
absence of the physiological remodelling of spiral arteries [9].  This creates a hypoxic, oxidative 
stressed microenvironment, which produces factor(s) that lead to the clinical manifestation of PE 
[10].  
Successful placentation depends on the correct expression of angiogenic factor [11]. However, 
this is compromised in PE where there is an imbalance between increased expression of the anti-
angiogenic soluble fms-like tyrosine kinase-1 (sFlt-1) and Endoglin (Eng) with a concurrent 
decrease in the pro-angiogenic placental growth factor (PlGF) and vascular endothelial growth 
factor (VEGF) [12, 13]. The systemic release of sFlt-1 pre-empts the discharge of cytokines such 
as tumour necrosis factor (TNF)-α which contributes to an exaggerated inflammatory response 
[14].  
During embryonic development acidic fibroblast growth factor (aFGF; FGF1; FGF-1) and basic 
fibroblast growth factor (bFGF; FGF2; FGF-2) are expressed as angiogenic factors [15]. Acidic 
fibroblast growth factor and FGF-2 are members of the super FGF family which is composed of 
22 ligands, with 4 receptors that act in a paracrine, intracrine and/or endocrine manner [16]. The 
heparan sulfate proteoglycan (HSPG) protects FGF-2 against degradation and confers high 
affinity for binding to its receptors [17].  The FGF-2 protein lacks signal peptides hence it is 
directly translocated across the plasma membrane and is secreted through autophagosomes or 
exosomes and by the non-conventional FGF-2/oligomerization with resultant membrane pore 
formation and by extracellular trapping mediated by HSPG on cell surfaces [18].  
The binding of FGF-2 to HSPG triggers a signal causing tyrosine kinase phosphorylation as well 
as its receptors activation [19]. The activated FGF-2 receptors then mediate signalling by 
recruiting specific molecules that bind to the phosphorylated tyrosine at their cytosolic part [20]. 
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Finally, this triggers a number of signalling pathways via the RAS/MAP kinase pathway, PI3 
kinase/AKT pathway and PLCγ pathway that mediate specific cellular responses [21]. 
Fibroblast growth factor-2 promotes cell growth, differentiation and proliferation [22]. It 
stimulates the migration and proliferation of endothelial cells in existing vessels leading to the 
formation of capillary tubes and recruits other cell types to generate and stabilise new blood 
vessels [23]. In hypertension, a vasopressor may be balanced by an up-regulation of FGF-2 
secretion that is initiated by the activity of the endothelial loop [24]. In the scenario of endothelial 
loop dysfunction such as in PE, FGF-2 secretion may be dysregulated [24]. 
In HIV infection, the HIV-1 (HIV-Tat) has similar properties to those of FGF-2 [18]. The 
transactivator of transcription Tat can also act in synergy with VEGF or FGF-2 to modulate 
angiogenesis [25]. In view of the role of FGF-2 and the high prevalence of PE and HIV infection 
in SA, this study attempts to examine the effect of FGF-2 in HIV associated PE based on 
pregnancy type (PE vs normotensive pregnancy), HIV status (HIV-ve vs HIV+ve) and across 
all study groups. 
 
Material and Methods 
Study population 
Following ethical approval (BCA 338/17), regulatory health authority permission and informed 
consent, pregnant women were recruited from a large regional hospital in KZN, SA.  The study 
population (n=80) was determined by the Fischer’s test and consisted of normotensive pregnant 
(n=40) and pre-eclamptic (n=40) women. These groups were further stratified according to HIV 
status into HIV+ve normotensive (n=20), HIV+ve PE (n=20), HIV-ve normotensive (n=20) and 
HIV-ve PE (n=20). Pre-eclampsia was defined as hypertension with systolic blood pressure ≥ 140 
mmHg or diastolic blood pressure ≥ 90 mmHg, measured on two occasions, no less than four 
hours apart, and with proteinuria (+1 urine dipstick test) after the 20th gestational week. HIV status 
was determined following a rapid HIV test.  
All newly HIV infected women were initiated on HAART. Exclusion criteria included those 
without informed consent, chorioamnionitis, eclampsia, chronic hypertension, intrauterine death, 
abruption placentae, diabetes, systemic lupus erythematous, chronic renal disease, polycystic 
ovarian syndrome, sickle cell disease, cardiac disease, pre-existing seizure disorders, active 




This is a retrospective study using archived venous blood. These were collected in K3-EDTA 
tubes, serum was extracted and stored in cryovials at -80⁰C until immunoassay. 
Bio-Plex Multiplex immunoassay 
The immunoassay was performed according to the manufacturer’s instructions (Bio-Rad 
Laboratories, Inc., USA). 
Maternal blood samples were collected in sterile tubes were centrifuged at 3000 rpm for 10 min 
at 4° C and serum was used for quantifying FGF-2 levels using the Bio-Plex Pro Human Cancer 
Biomarker Panel 1 (Bio-Rad Laboratory, Inc., USA). Standards were prepared in a 1:10 and 1:4 
dilution series, whilst samples were prepared in a 1:4 dilution. 
The immunoassay involved the incubation of the antigen sample, i.e., FGF-2, with the capture 
antibody-coupled beads. Subsequently, biotinylated detection antibody with streptavidin-
phycoerythrin (SA-PE), a reporter conjugate was added to the reaction. Following washing for 
removal of any unbound SA-PE, fluorescence of the SA-PE bounded to each bead was measured 
by a Bio-Plex Multiplex Reader. The analyte concentration was extracted in picograms per 
millilitre (pg/ml) using the Bio-plex manager software version 4.1.  
Statistical analysis 
Data analysis was performed using GraphPad Prism statistics software, version 5.00 (California, 
USA). The Student’s unpaired t-test was used to analyse parametric data (mean ± standard 
deviation) and the Mann-Whitney U test was used to measure non-parametric data (median ± 
inter-quartile range). An analysis of variance (ANOVA) was performed to compare difference of 
serum FGF-2 concentration in the sample population based on HIV status (HIV+ve vs HIV-ve) 
and pregnancy type [normotensive vs pre-eclamptic]. A probability level of p< 0.05 was 
considered statistically significant. 
 
Results 
Clinical characteristics and demographic data 
Table 1 provides a summary of the demographics of the study population. Gestational age, 
diastolic and systolic blood pressures (BP) were statistically different between the normotensive 
and PE groups (p<0.0001: Mann-Whitney test). There were no significant differences in maternal 
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age (p=0.14) and maternal weight (p=0.5) between normotensive vs PE groups. Proteinuria was 
noted in all cases of PE and HAART were given to all HIV positive women. 
The mean ± standard deviation of maternal body mass index was 28.76.86±6.79 kg/m2 vs 
32.84±8.12kg/m2 for normotensive and for PE groups respectively. The mean ± standard 
deviation of baby weight from the normotensive versus PE pregnant group was 3.18±0.37 vs 
2.14±0.57 kg; Mann-Whitney test. 
Table 1: Clinical profile and demographic data of participant across all study groups. 















25.3±1.322 28.84 ±1.447 26.21±1.761 29.11±1.459 0.1446 
Gestational 
age (weeks) 
39.37±0.4133 38.53±0.4733 32.63±1.140 31.05±0.927 ***<0.0001 
Diastolic BP 
(mmHg) 
67.10±2.035 67.42±2.016 104.4±1.813 107.3±2.254 ***<0.0001 
Systolic BP 
(mmHg) 
120.3±2.285 114.6±2.696 159.3±3.500 163.7±3.25 ***<0.0001 
Maternal 
weight (kg) 
77.36±2.971 76.17±3.654 76.63±4.762 77.04±5.586 0.9096 
Parity 1.053±0.3008 1.47±0.2662 0.894±0.2405 1.316±0.2301 0.2350 
Data are presented as Mean± standard deviation, a one-way ANOVA test was used for statistical 






Figure 1: FGF-2 expression based on HIV status. *p=0.0471. Results are represented as 
Mean±Standard deviation. 
 









































 Figure 3: FGF-2 expression across all study groups. **p=0.0020 Results are represented as 
Mean±Standard deviation; 
 














FGF-2 (pg/ml) 64.63 (77.03) 11.81(58.87) 11.81(26.58) 11.81(0) ** 0.0020 
Results are represented as: median (interquartile range)  
 
FGF-2 serum concentration  
Concentrations of FGF-2 across study group are outlined in table 2 and figures 1, 2 and 3. 
HIV status: Based on HIV status (figure 1), there was a significant difference of serum FGF-2 
between the HIV-ve versus the HIV+ve groups (52.15±9.491 pg/ml vs 33.80±9.622 pg/ml; Mann 
Whitney U=544.5; p = 0.0471) respectively. 
Pregnancy type: Based on pregnancy type (figure 2), there was a significant difference of serum 
FGF-2 between normotensive and pre-eclamptic groups (61.79±11.25 pg/ml vs 25.38±6.690 


























Across study groups: A significant difference of serum FGF-2 expression was noted across all 
groups (figure 3) i.e., normotensive HIV-ve vs pre-eclamptic HIV-ve [69.34±13.83 pg/ml vs 
35.83±12.26 pg/ml; p=0.0255]; normotensive HIV-ve vs pre-eclamptic HIV+ve  [69.34±13.83 
pg/ml vs 13.78±1.969 pg/ml; p = 0.0002] and normotensive HIV+ve vs pre-eclamptic HIV+ve 
[53.81±18.17 pg/ml vs 13.78±1.969 pg/ml; p = 0.0149]. 
 
Discussion  
Elevated levels of FGF-2 have been implicated in the pathogenesis of several diseases 
characterized by a dysregulated angiogenic/inflammatory response, including cancer [26]. In 
contrast, our study reports that FGF-2 expression was significantly down-regulated in PE 
compared to normotensive pregnancies. The disparity in FGF-2 levels may be attributed to the 
lowered angiogenesis in PE.  Since FGF-2 is a mitogen for endothelial cells, our results are 
congruent with the physiological absence of myometrial spiral artery remodelling that occur in 
PE. Moreover, vasopressors such as endothelin and angiotensin II correlate with an increase in 
serum FGF-2 content in hypertension [27]. Similarly, the work of Ozkan et al. (2008) 
reports a significant increase of FGF-2 immunostaining in chorionic villi and in 
amniochorionic membranes of PE. The latter author suggests that the low serum FGF-2 
levels observed in severe compared to mild PE may be explained by the severity of endothelial 
damage [28]. A limitation of our study was the heterogeneity of the study population, early onset 
and late onset PE may reflect varying degrees of endothelial damage [29]. 
Notably, both FGF and VEGF are potent angiogenic factors [30]. Preeclampsia is associated with 
hypoxia and an oxidative stressed microenvironment [31]. Oxidative stress controls the steroid 
receptor coactivator 3 (Src-3) expression, influencing angiogenesis through the PI3K/Akt/mTor 
signaling pathways [32].  VEGF-induced angiogenesis requires integrin αvβ5 unlike, FGF-
induced angiogenesis hinges on ligation of integrin αvβ3, rather than Src kinase activity [33]. 
Also, FGF-2 mediated angiogenesis is blocked by mitogen-activated protein kinase inhibitor, 
PD98059 [34]. 
Preeclampsia characterised by an ischemic placenta and hypoxia that induces the release of stored 
FGF-2 from damaged extracellular matrix. The enhanced FGF-2 promote proliferation and 
differentiation of endothelial cells and tissue repair [35]. Umbilical vein endothelial cell line 
(HUVE-12 cells) cultured under hypoxic conditions produced higher FGF-2 levels when 
compared to cells that are maintained under normal condition [35]. The increased FGF-2 is 
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associated with duration of hypoxia [36]. The FGF-2 down-regulation reported in our study may 
be attributed to the dysregulated endothelial loop feedback mechanism.  
Furthermore, matrix metalloproteases (MMPs) mediate trophoblast cell invasion [37]. Matrix 
metalloproteinase 9 (MMP9) is an endopeptidase responsible for ECM degradation specifically 
[37].  Tissue inhibitor of metalloproteinase 1 (TIMP1) is an inhibitor of MMP9. The balance 
between MMP9 and TIMP1 influences cell permeation [38, 39]. This homeostasis correlates 
negatively with FGF-2 levels in HUVE-12 cells; suggesting that endothelial FGF-2 release may 
contribute to MM9/TIMP1 regulation [40]. In breast cells, FGF-2 promotes MMP9 secretion 
through the Ras/ERK signalling pathway [41]. Since MMP-9 mediates the discharge of FGF-2 
[42], the FGF-2 decline in our study probably indicates the inhibition of ECM proteolysis with 
the subsequent inadequate trophoblast invasion of PE.   
Our study reports a down-regulation of FGF-2 in HIV infected women compared to uninfected 
women, irrespective of pregnancy type. These result are corroborated by [43] who demonstrated 
a high serum FGF-2 in untreated HIV infected patients compared to HIV infected patients on 
HAART. 
The HIV-1 Tat protein is a potent angiogenic factor since the Tat arginine- and lysine-rich 
sequence is similar to that of VEGF-A [44]. During HIV infection, VEGF, FGF-2 and Tat work 
in synergy to modulate endothelial cells phenotype [25]. Fibroblast growth factor-2 was shown 
to synergize with HIV-1 Tat protein and promotes Bcl2 that prevents endothelial cell apoptosis 
via p53 inhibition [23]. HIV-1 via gp120 to the negative charge of HSPG on endothelial cells 
amplifying viral infectivity and facilitating the release of Tat [45]. The Tat protein competes 
with FGF-2 for binding to HSPG on cell surfaces and within the ECM [46]. The combined Tat 
FGF-2 is likely dependant on FGF-2 capability of inducing the expression of 
the αvβ3 and α5β1  integrins which, in turn, function as Tat receptors [46]. The Tat also binds and 
activates the Flk-1/kinase insert domain receptor (Flk-1/KDR), a VEGF-A tyrosine kinase 
receptor independent of FLT-1 [47]. It is therefore plausible that Tat interaction with HSPG/FGF-
2 on endothelial cells contributes to the characteristic pathognomic lesion of endotheliosis that 
occurs in PE. In our study, the FGF-2 downregulation in HIV positive group could be due to 
antiretroviral administration that may have confounded the action of Tat [44].  
Notably, antiretroviral therapy (ART) is implicated in FGF dysregulation and may account for 
the downregulation of FGF-2 observed in our study. Antiretroviral drugs affect FGF21–obligatory 
co-receptor β-Klotho expression in an in vitro model using human cells [48]. Intracellular ER 
stress/oxidative stress triggered by ART causes induction of FGF. In addition, several studies 
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have reported dysregulation in FGF21 [49-51].  In addition, HAART treatment increases TNF-α 
which has anti-apoptotic and anti-viral replication effects. 
Gestational age correlates with the severity of PE [52]. In our study, the gestational age varied 
amongst study groups. The PE group irrespective of HIV status delivered at an earlier gestational 
period compared to the normotensive group. PE is also associated with intrauterine growth 
restriction [53]. 
Limitations 
Limitations of this study include a small sample size as well as non-stratification of PE into early 
and late sub-type. PE is a heterogeneous disease, where EOPE is associated with defective 
trophoblast invasion [54]. Another limitation of this study is that all HIV infected individuals 
were on dual anti-retroviral (HAART and nevirapine) management.  
 
Conclusion 
In conclusion, this study demonstrates a significant down-regulation of FGF-2 in preeclamptic 
compared to normotensive pregnancies. These results echo a hypoxic oxidative stressed 
microenvironment that reflects deregulated angiogenesis with a dysfunctional endothelial loop 
that affects the FGF secretory mechanism leading to the deficient trophoblast invasion in PE.  
In contrast, we report a significant downregulation of FGF-2 in HIV infection where 
VEGF, FGF-2 and Tat work in synergy to modulate endothelial cell phenotype and 
angiogenesis. The expression of FGF-2, has potential as a predictive risk indicator value 
for the early detection in HIV associated PE. 
However, the management of comorbidities (PE) resulting from the side effect of HAART on 
FGF in HIV infected pregnant women warrants investigation. Future studies will include a genetic 
appraisal of the variants FGF-1 rs34011 and FGF-2 rs2922979 in African women with PE. 
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Sub Saharan Africa has many challenges in maternal health management (Sebitloane et al., 2017). 
In South Africa, 13.1% of the total population is HIV positive, the 4th highest prevalence rate 
globally (Statistics South Africa, 2018, UNAIDS, 2016). Human Immunodeficiency Virus 
infection/AIDS and PE are the leading causes of maternal and perinatal morbidity and mortality 
in SA (Sebitloane et al., 2017). In SA, 40% of pregnant women are found to be HIV infected 
(Saving Mothers Report 2014-2016, 2017). The province of KZN is the global “HIV hotspot” 
where 40.8% of adults (aged 15 years and older) are living with HIV infection (Cuadros et al., 
2018). This province also has a PE prevalence of 12% (Moodley et al., 2018). 
As PE affects both the mother and foetus, predictive tests early in pregnancy would have a greater 
impact in reducing the morbidity and mortality (Magee et al., 2014). A number of angiogenic 
factors such as sFlt-1 and PlGF have been proposed in the prediction of PE (Vatten et al., 2007; 
Rana et al., 2013). The sFlt-1:PlGF ratio has been approved as a diagnostic aid for preeclampsia 
in conjunction with other clinical findings (Zeisler et al., 2016).  
Basic fibroblast growth factor is a potent mitogen and angiogenic factor that contributes to cell 
growth, differentiation, and angiogenesis, hence would be implicated in PE aetiology (Ornitz and 
Itoh, 2015). In vitro studies report that FGF-2 induces endothelium-derived de novo synthesis of 
vasodilators such as endothelial nitric oxide (NO) (Hohlagschwandtner et al., 2002). Circulating 
FGF-2 levels are reported to be elevated in PE (Ozkan et al., 2008, Hohlagschwandtner et al., 
2002).  In view of the absence of data on PE comorbid with HIV infection, our study evaluates 
FGF-2 expression in HIV associated PE. 
In our study, a downregulation of FGF-2 expression was noted in PE compared to normotensive 
pregnant women irrespective of their HIV status. FGF-2 is produced by endothelial cells and 
fibroblast (Pintucci et al., 2002). PE is a state of endotheliosis and has a heightened inflammatory 
milieu, hence FGF-2 is released albeit lower (Moscatelli et al., 1986). The circulating free FGF-
2 acts in repairing endothelial cell damage and promoting angiogenesis (Tepper et al., 2004).  
FGF binds with HSPG present within the ECM where it triggers a signal that initiates tyrosine 
kinase phosphorylation and FGFR activation (Ornitz and Itoh, 2015). This results in a cascade of 
phosphorylation events via the RAS/MAPK pathway, PI3 kinase/AKT signalling pathways, and 
the PLCγ pathway that control migration (Murakami et al., 2007). Notably, the consequences of 
the inhibition of FGFR phosphorylation promotes aberrant protein activation that explains the 
abnormal invasion of the trophoblast population associated with the PE (Yang et al., 2011) and 
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explains the FGF downregulation expressed in our study. Nonetheless, in contrast to our findings, 
elevated levels of FGF-2 have been implicated in the pathogenesis of several diseases 
characterized with a deregulated angiogenic/inflammatory response such as cancer (Andrés et al., 
2009). Similarly, FGF-2 expression was reported to be upregulated in PE compared to 
normotensive pregnancies (Hohlagschwandtner et al., 2002).  
Nonetheless Ozkan et al (2008) suggested an upregulation of FGF-2 in mild PE concurrent with 
a downregulation of FGF-2 in severe PE due to the severity of endothelial damage. In severe PE, 
the endothelial loop is subject to major damage compared to mild PE, implicating less FGF-2 
release, hence the inadequate trophoblast invasion that occurs in PE. A limitation of our study 
was the non-stratification of the study population by disease severity into mild or severe type or 
by gestational age into EOPE and LOPE.  
PE is associated with a hypoxic microenvironment associated with high reactive oxidative stress 
(Verma et al., 2018). Both FGF and VEGF are powerful angiogenic factors (Cao et al., 2004).  
Hypoxia induces the release of stored FGF-2 from a damaged extracellular matrix (Cao et al., 
2004). The enhanced FGF-2 promotes proliferation and differentiation of endothelial cells and 
tissue repair (Lindner et al., 1990). Oxidative stress regulates the steroid receptor coactivator 3 
(Src-3) expression, manipulating angiogenesis via the PI3K/Akt signaling pathways (Reuter et 
al., 2010). 
Since FGF is a mitogen for endothelial cells, our results are congruent with the physiological 
absence of myometrial spiral artery remodelling that occurs in PE. Moreover, vasopressors such 
as endothelin and angiotensin II correlate with low serum levels of FGF content in hypertension 
(Hohlagschwandtner et al., 2002).  
Endothelial FGF-2 release may contribute to MM9/TIMP1 regulation (Luo et al., 2011). FGF-2 
promotes MMP9 secretion through the Ras/ERK signaling pathway (Luo et al., 2011). The FGF-
2 decline in our study probably indicates the inhibition of ECM proteolysis with the subsequent 
inadequate trophoblast invasion of PE.   
According to HIV status, we report a downregulation of FGF-2 in HIV positive compared to HIV 
negative pregnant women irrespective of pregnancy type. Our results were found to be in contrast 
to those of (Barillari et al., 1999), who reported a high expression of FGF-2 in HIV positive 
infection. HIV Tat protein is a transactivator of viral gene expression and is released 
extracellularly in HIV acute infection (Romani et al., 2010).  Biologically, this HIV regulatory 
protein Tat acts in synergy with FGF-2. Both FGF-2 and VEGF, are potent angiogenic factors 
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that are highly expressed in AIDS, where they synergize in promoting neoangiogenesis and 
oedema (Zhou et al., 2013). 
Since Tat has a similar arginine and lysine-rich sequence to VEGF it is a powerful angiogenic 
factor (Zhou et al., 2013). Tat induces endothelial cells to migrate, adhere and grow as a capillary-
like network in vitro (Barillari et al., 1999). HIV Tat has also been shown to bind F1K-1/KDR, 
one of the receptors for the VEGF, suggesting an additional mechanism for Tat to exert its 
angiogenic effect (Albini et al., 1996). Moreover, Tat exerts activities that are linked to diseases 
of vascular origin such as in Kaposi sarcoma, hence would also correlate with PE (Zhou et al., 
2013).  
During HIV infection, VEGF, FGF-2, and Tat work in synergy to modulate endothelial cells 
phenotype (Das et al., 2016). FGF-2 works in concert with Tat and promotes Bcl2 that impedes 
endothelial cell apoptosis via p53 blockade (Sgadari et al., 2011). The inoculation of Tat alone in 
nude mice has little or no effect, however, when injected with a small amount of FGF-2, it 
promotes the development of angio-proliferative lesions in the inoculated animal (Sgadari et al., 
2011). The Tat protein contests with FGF-2 for binding to HSPG on the plasmalemma and within 
the ECM (Alghisi and Rüegg, 2006).  
Tat can promote endothelial cell adhesion through the binding of its arginine-glycine-aspartic acid 
(RDG) region to the αvβ3 and α5β1integrins and the VEGFR-2/KDR via the basic domain of Tat 
(Zhou et al., 2013). The combined Tat/FGF-2 effect is due to FGF-2 inducing the expression of 
the αvβ3 and α5β1  integrins, which aids Tat binding (Alghisi and Rüegg, 2006). HIV-1 via gp120 
binds to HSPG on endothelial cells amplifying viral infectivity thereby expediting the release of 
Tat (Crublet et al., 2008).  
Tat causes aberrant cell signaling and leads to altered endothelial cell morphology, gene 
expression, and survival. HIV-1 Tat protein stimulates the MAPK pathway in primary T cells 
which is connected with the movement from G0 to G1 phase in naïve T cells enabling productive 
HIV infection (Li et al., 1997). HIV-1 also utilizes the Tat protein to hijack intracellular functions 
and evades the immune response of the host, and thus may contribute to the high inflammatory 
response in HIV associated PE (Abbas and Herbein, 2013) 
The FGF-2 downregulation in the HIV positive group observed in our study could also possibly 
be due to HAART. In our study, all HIV positive women received HAART and nevirapine, as 
part of the standard of HIV treatment in SA. HAART acts by suppressing HIV-1 viral load by 
restoring natural killer cells NK ability to secrete chemokines. In pregnancy, this NK activation 
has negative effects as it may inhibit trophoblast invasion which is associated with PE (Phoswa 
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et al., 2018).  Clinical and in vitro studies suggest that the long-term use of HAART results in 
endothelial toxicity and vascular dysfunction (Francisci et al., 2009).   
Conclusion 
This study demonstrates a downregulation of FGF-2 in PE compared to normotensive pregnant 
women irrespective of HIV status reflecting endothelial damage congruent with FGF secretion. 
The downregulation of FGF-2 in HIV positive compared to HIV negative irrespective of 
pregnancy type may be attributed to the non-phosphorylation of HIV regulatory protein tat or to 
the MAPK pathway inhibition. Notably, the use of HAART results in endothelial toxicity and 
vascular dysfunction which affect FGF expression. Future studies will include a genetic appraisal 
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